Revotar Biopharmaceuticals Ag

Merck Patent Gmbh

Ewald Aydt

Remo Kranich

Herwig Buchholz

Junyou Pan

Anke Busemann

Amir Hossain Parham

Philipp Stoessel

Christof Pflumm

Anja Jatsch

Dominik Joosten

Joachim Kaiser

Karin Vollhardt

Gerhard Wolff

The present invention relates to soluble organic compounds, to compositions comprising these compounds, to formulations comprising the compounds or compositions, and to electronic devices.

Organic compounds with soluble groups

The present invention relates, inter alia, to dermal systems comprising at least one light source and at least one pharmaceutically and/or cosmetically active ingredient. The dermal systems can be employed in order to enhance the penetration and action of the pharmaceutically and/or cosmetically active ingredient.

Enhancement of penetration and action

Described is a dermal system which contains at least one light source and at least one pharmaceutically and/or cosmetically active ingredient. The dermal system can be employed in order to enhance the penetration and action of the pharmaceutically and/or cosmetically active ingredient. The at least one light source is a thin light source comprising at least one inorganic light emitting diode (LEDs) and/or at least one organic light emitting device.

The present invention relates inter alia to functional materials for the treatment and/or prophylaxis and/or diagnosis of diseases and/or cosmetic conditions. The functional materials can be used for the preparation of light emitting devices comprising fibers as light emitting elements.

Fibers in therapy and cosmetics

The present invention relates to a cells and cell tissue treatment device and use thereof.

Device and method for treatment of cells and cell tissue

The present invention relates inter alia to light emitting fibers for the application in general lighting, display backlit, information display, and for treatment and/or prophylaxis and/or diagnosis of diseases and/or cosmetic conditions. The fibers can be used for the preparation of any kind of canvas and light emitting devices.

Radiative fibers

Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning &#x2014;X&#x2014; is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or selectin binding.

Phloroglucinol derivatives having selectin ligand activity

Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning &#x2014;X&#x2014; is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Aromatic compounds and their use in medical applications

Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols, indices and substituents have the following meaningR&#x2550;H, CN, NO, CF, F, Cl, Br, I, CHR&#x2550;H, CN, NO, CF, F, Cl, Br, I, CH, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl andeither Ror Rmust be HR&#x2550;H, CN, NO, CF, F, Cl, Br, I, CH, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolylthen X is e.g.   or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formulas (Ia) or (Ib). The compounds are applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Non-glycosylated/non-glycosidic/non-peptidic small molecule PSGL-1 mimetics for the treatment of inflammatory disorders

The novel crystalline and polymorphic forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-&#x3b1;-D-mannopyranosyloxy)-phenyl] hexane have advantageous properties and can be used in pharmaceutical and dermatological compositions.

Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-&#x3b1;-D-mannopyranosyloxy)-phenyl] hexane

Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning&#x2014;X&#x2014; is e.g.  or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning  or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Hydroxylated aromatic compounds

Pharmaceutical compositions comprising at least one compound of e.g. the formulas (Ie) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning&#x2014;X&#x2014; is e.g. and Y is e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Growing community of inventors

Berlin, Germany

Ewald Aydt